Home Top Movers Is This Why The ARDX Stock Rose Last Trading?

Is This Why The ARDX Stock Rose Last Trading?

Ardelyx Inc. (NASDAQ: ARDX) opened Wednesday’s trading session at $7.25 and achieved its intraday high of $8.17. Ardelyx stock closed the trading session at $7.84, rising 8.89%. The Ardelyx stock remained very active on Wednesday, recording a greater than 128.72% trading volume compared to the average daily trading volume. The ARDX stock traded 2.58 million shares on Wednesday, more than the daily average volume of 1.10 million.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

News of the start of four phase 3 trials by its partner sent the ARDX stock soaring.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


What actually happened?

Ardelyx aims to enhance the lives of patients with kidney and cardiorenal diseases by discovering, developing, and commercializing first-in-class medicines. ARDX is developing tenapanor for control of serum phosphorus in adults with chronic kidney disease on dialysis. Its NDA is currently being reviewed by the FDA, and a PDUFA date of April 29, 2021, is scheduled.

Read More

ARDX is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium levels that occur in patients with a number of kidney and/or heart diseases, and is working on metabolic acidosis in patients with congestive heart failure.

Ardelyx announced yesterday that its collaboration partner in Japan, Kyowa Kirin Co. has initiated four Phase 3 clinical studies in Japan assessing the efficacy and safety of tenapanor in the treatment of hyperphosphatemia.

ARDX will be remunerated with a $5 million payment if this development milestone is achieved.

Phase 3 clinical trials consist of the following:

  • A randomized, double-blind, control-group comparative study on randomized, double-blind, controlled, and placebo-controlled subjects;
  • A parallel group comparison of phosphate binder combinations;
  • A single-arm open-label study evaluating patients taking dialysis for hyperphosphatemia;
  • Long term study in Japan, looking at serum phosphorus in patients switching from one or more phosphate binders to tenapanor for hyperphosphatemia.

    Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Finally,

Based on Ardelyx (ARDX) analysis, tenapanor, alone or combined with sevelamer carbonate, is capable of significantly lowering phosphorus levels. Despite treatment with low doses of sevelamer or tenapanor, patients exhibited a mean serum phosphorus reduction after nearly one year. The current clinical trials will be assessing the ability of ARDX to demonstrate that reduction as well.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Explains MOGO Stock Going Up Today?

The Mogo Inc. (NASDAQ: MOGO) stock has gained 5.04% to $8.55 in premarket trading today. Mogo stock finished last trading day at $8.14, down...

Zynga Inc. (ZNGA) stock rises in the Pre-Market: What’s going on?

Zynga Inc. (ZNGA) announced its first-quarter 2021 financial results after which the ZNGA stock happened to be green after underperformance in the last trade....

American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded

American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

Sally Beauty Holdings (NYSE:SBH) stock surged in the current trading session; here’s why

In the current trading session, Sally Beauty Holdings Inc. (SBH) stock had surged by 19.69% to $24.25 at the time of writing. SBH stock...

Moderna Inc. (NASDAQ: MRNA) stock declines during current market. Let’s figure out why?

Moderna Inc. (NASDAQ: MRNA) stock falls by 5.31% in the current market trading after MRNA has announced its financial results for Q1 2021. Moderna...

Related News

Himax Technologies, Inc. (HIMX) Stock Climbing After Promising Q1 2021 Financial Reports

Himax Technologies, Inc. (HIMX) stock prices were down by 6.97% as of the market closing on May 5th 2021, bringing the price per share...

Why BioCryst Pharmaceuticals, Inc. (BCRX) stock is climbing today?

BioCryst Pharmaceuticals, Inc. (BCRX) announced its first-quarter 2021 financial results after which the BCRX stock happened to be green as its per-share price went...

Precipio, Inc. (PRPO) Stock Trending Up Following Successful Launch of Covid-19 Antibody Testing Kit

Precipio, Inc. (PRPO) stock prices were down 3.62% as of the market closing on ay 5th 2021, bringing the price per hare down to...

Shares of Cinedigm Corp. (CIDM) are climbing high in the premarket. What’s Going On?

Cinedigm (NASDAQ:CIDM), a distributor of various movies, television and other digital content, managing a library of distribution rights to several thousand titles and different...

Why Stealth BioTherapeutics Corp (MITO) stock is soaring in Pre-Market today?

Stealth BioTherapeutics Corp (MITO) presented the data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is collected...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.